Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. The company’s primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). Products and Drug Candidates Hepatitis C The company is developing nucleotide polymerase inhibitors and NS5A inhibitors to inhibit HCV replication. Nucleoside/Nucleotide Polymerase Inhibitors: During HCV replication, the viral polymerase, also called the NS5B polymerase, is the key enzyme that replicates the viral genetic information contained in the HCV viral genetic material, which is known as viral ribonucleic acid and is therefore essential for the virus to reproduce itself. Nucleosides/nucleotides are small, natural chemical compounds that function as the building blocks of human and viral genetic material. Nucleoside polymerase inhibitors prevent HCV replication by interfering with the activity of the viral polymerase. NS5A Inhibitors: NS5A is a multifunctional, nonstructural HCV protein that is primary for the formation of viral replication complexes, the process of viral replication, and virus assembly. Nucleotide Polymerase Inhibitors Development: IDX184 is a novel liver-targeted nucleotide prodrug that enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, thus improving drug efficacy and limiting systemic side effects. IDX184 has demonstrated activity across multiple HCV genotypes, a high barrier to resistance and synergy with ribavirin in vitro. In 2012, the company enrolled the phase II study of IDX184. It also submitted an investigational new drug application for IDX19368, a next generation nucleotide polymerase inhibitor drug candidate. NS5A Inhibitor Development: The company’s lead drug candidate for its NS5A inhibitor program is IDX719. In 2012, it completed the second part of the phase I study, single-ascending doses of IDX719 in HCV genotype 1, 2 and 3-infected patients. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for IDX719. In January 2013, the company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen) for the clinical evaluation of all oral DAA HCV combination therapies. The combination therapies involve IDX719, its once-daily pan-genotypic NS5A inhibitor, simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen and Medivir AB, and TMC647055 boosted with low dose ritonavir, being developed by Janssen. Other DAA Drug Candidates: The company’s lead drug candidate for its non-nucleoside polymerase inhibitor program is IDX375, a novel palm-binding polymerase inhibitor. Human Immunodeficiency Virus Type-1 (HIV) The company developed a non-nucleoside reverse transcriptase inhibitor drug candidate, IDX899, for the treatment of HIV, and acquired immune deficiency syndrome for use in combination therapy. The company completed a proof-of-concept clinical trial of IDX899 in treatment-naïve HIV-infected patients. Hepatitis B In collaboration with Novartis Pharma AG, the company developed Tyzeka/Sebivo through commercialization for the treatment of patients with hepatitis B virus (HBV). The FDA approved Tyzeka in the United States and Sebivo in approximately 50 countries outside the United States, including major Asian countries and various countries included in the European Union. Research and Development Expenses The company’s research and development expenses were $70.2 million for the year ended December 31, 2012. Patents and Licenses Hepatitis C Patent Portfolio: The company’s HCV patent portfolio includes approximately 26 issued U.S. patents, approximately 22 pending U.S. patent applications, approximately 69 granted foreign patents, and approximately 175 pending foreign patent applications. Hepatitis B Patent Portfolio and Licenses: The company’s HBV patent portfolio includes approximately 12 issued U.S. patents, approximately 1 pending U.S. patent application, approximately 50 granted foreign patents, and approximately 4 pending foreign patent applications, including patents pertaining to telbivudine. HIV Patent Portfolio: The company’s HIV patent portfolio includes approximately 7 issued U.S. patents, 1 pending U.S. application, approximately 70 granted foreign patents, and approximately 40 pending foreign patent applications. Regulatory Matters The company is subject to federal, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposing of hazardous materials and waste products, including certain regulations promulgated by the U.S. Environmental Protection Agency. History Idenix Pharmaceuticals, Inc., a Delaware corporation, was founded in 1998.
idenix pharmaceuticals inc
60 Hampshire Street
Cambridge, MA 02139
|Bristol-Myers Squibb Co||$51.08 USD||0.00|
|GlaxoSmithKline PLC||1,595 GBp||+2.50|
|Vertex Pharmaceuticals Inc||$67.33 USD||0.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- Detroit, MI | Wayne State UniversityPosted: Nov 26
- New York, NY | AGORAPosted: Nov 25
- New York | Northrop GrummanPosted: Dec 04
- Lewiston, ME | Walmart MilitaryPosted: Dec 04
Sponsored Financial Commentaries
To contact IDENIX PHARMACEUTICALS INC, please visit www.idenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.